Choice Institutional Equities issued a buy rating for Park Medi World with a target price of Rs 350. The firm expects growth from a 6,590-bed pipeline operational by December 2028. Despite temporary cost pressures, analysts believe the hospital chain is well-positioned for long-term success through its disciplined expansion and specialty mix.

Choice Institutional Equities's report on Park Medi World Growth visibility supported by disciplined expansion and improving business mix: PARKHOSP remains well-positioned for a sustained longterm growth, underpinned by its 6,590-bed pipeline to be operational by December 2028. Additional growth drivers include its cluster-led expansion strategy, improving specialty mix, gradual shift towards a higher private-pay payer mix and healthy ARPOB growth. While the near-term margin is negatively impacted by new hospital ramp-up and one-off cost pressure, we expect these transitory headwinds to normalise over the next few quarters.

Further, the recently-announced oncology drug trade-margin cap is anticipated to have a negligible impact on profitability. We forecast Revenue/EBITDA/PAT to expand at a CAGR of 28.0%/28.0%/31.4% over FY26-29E. Outlook Rolling forward our valuation to 18x average FY28-FY29E EV/EBITDA, we retain our 'BUY' rating with a target price of INR 350. For all recommendations report, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Park Medi World - 1611026 - choice